Results 71 to 80 of about 28,326 (256)

Advances in Clinical Application of ctDNA in Tumor Detection, Screening, Prognosis and Treatment

Zhongliu Fangzhi Yanjiu, 2020
Circulating tumor DNA (ctDNA) is a tumor-derived fragmented DNA in blood and is a characteristic marker of tumor. Through the correlative detection of ctDNA, the trace information of the tumor in the blood of the patients can be detected, and the ...
LIU Yong
doaj   +1 more source

Abstract 744: ctDNA use in molecular diagnostics

, 2017
The analysis of circulating cell-free tumor DNA (ctDNA), which can be obtained from plasma by non-invasive procedures, is expected to provide useful biomarkers in the management of non-small-cell lung cancer (NSCLC) patients. Indeed, several studies have
Elena DalCin, Maria Giulia Cangi, Alessandra Bulotta, Gilda Magliacane, Greta Grassini, Vanesa Gregorc, Lorenza Pecciarini, Ilaria Francaviglia, Chiara Lazzari, Monika Ducceschi, Claudio Doglioni   +10 more
core   +1 more source

Revolutionizing Healthcare With Paper‐Based Nucleic Acid Testing

Exploration, EarlyView.
This work summarizes strategies to enhance paper‐based devices for nucleic acid testing. Key approaches include optimizing paper platforms, improving nucleic acid amplification, and refining labeling/signaling methods. These advancements aim to boost sensitivity, speed, and usability, making paper‐based diagnostics more effective for point‐of‐care ...
Hong Zhang, Yi Yang, Heng Li, Xiaolin Hu, Hui Xiao, Dou Wang, Sergio Benardini, Wei Gu, Yang Luo   +8 more
wiley   +1 more source

Circulating Tumor DNA in Primary and Secondary Liver Cancers: A Comprehensive Review

Frontiers in Bioscience-Scholar
Similar to many other cancer types, liver malignancies pose the common challenges of late detection of primary tumors and recurrences. Liquid biopsies, which assess the presence of circulating tumor DNA, have emerged as a novel, non-invasive clinical ...
Hanna Hong, Chase J Wehrle, Omer Faruk Karakaya, Noah Tocci, Pranav Kumar, Keyue Sun, Chunbao Jiao, Sangeeta Satish, Rebecca Panconesi, Jamak Modaresi Esfeh, Maureen Whitsett Linganna, Koji Hashimoto, Andrea Schlegel, Charles Miller, David C.H. Kwon, Federico Aucejo   +15 more
doaj   +1 more source

High fragmentation characterizes tumour-derived circulating DNA. [PDF]

PLoS ONE, 2011
BACKGROUND: Circulating DNA (ctDNA) is acknowledged as a potential diagnostic tool for various cancers including colorectal cancer, especially when considering the detection of mutations.
Florent Mouliere, Bruno Robert, Erika Arnau Peyrotte, Maguy Del Rio, Marc Ychou, Franck Molina, Celine Gongora, Alain R Thierry   +7 more
doaj   +1 more source

Current Utility and Future Applications of ctDNA in Colorectal Cancer [PDF]

, 2019
Circulating tumour DNA (ctDNA) shows promise as a minimally invasivebiomarker with a myriad of emerging applications including early detectionand diagnosis, monitoring of disease and treatment efficacy, and identificationof actionable alterations to ...
Segelov, Eva, Green, Maja, Sophia Frentzas, Day, Daphne, Daphne Day, Cameron A. Naidu, Eva Segelov, Maja Green, Frentzas, Sophia, Naidu, Cameron Ashley   +9 more
core   +1 more source

Dataset of RNAseq, TCR and ctDNA

, 2021
This dataset includes gene expression matrix by TPM normalization, TCR clonality and ctDNA ...
Jianming Xu (11288670)
core   +1 more source

Anatomical Understanding and Evolution of Surgical Treatment for Cancer of the Esophagogastric Junction: From Anatomical Controversies to Precision Surgery

Gut Medicine, EarlyView.
ABSTRACT The incidence of cancer of the esophagogastric junction (EGJC) has surged globally. Historically, its unique anatomical position and dual histological characteristics generated significant controversy regarding tumor classification and surgical strategies.
Cien Sun, Hao Liu, Dehua Ma, William C. Cho, Pasan Witharana, Jianfei Shen   +5 more
wiley   +1 more source

ctDNA Reveals Targetable Alterations [PDF]

Cancer Discovery, 2020
Abstract In the plasmaMATCH trial, researchers performed circulating tumor DNA testing on patients with advanced breast cancer and matched those with ESR1, HER2, or AKT1 alterations to targeted therapies. Patients with HER2 and AKT1 mutations experienced response rates greater than 22% with durable benefit.
openaire   +1 more source

The Role of Multicancer Early Detection Tests in Head and Neck Squamous Cell Carcinoma: A Case Series

Head &Neck, EarlyView.
ABSTRACT Background Head and neck squamous cell carcinoma (HNSCC) lacks an established screening program, and most cases are diagnosed at advanced stages. Multi‐cancer early detection (MCED) blood‐based assays represent a promising approach, yet real‐world clinical experience with MCED‐identified HNSCC remains limited.
Abhinav Talwar, Olivia Ben‐Levy, Nikhil Sriram, Sandeep Samant   +3 more
wiley   +1 more source